Drug Profile
Thyromimetic - Bayer
Latest Information Update: 25 Feb 2003
Price :
$50
*
At a glance
- Originator Bayer
- Class
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 25 Feb 2003 No development reported - Preclinical for Atherosclerosis in Europe (PO)
- 25 Feb 2003 No development reported - Preclinical for Hyperlipidaemia in Europe (PO)
- 08 Mar 2001 Preclinical development for Atherosclerosis in Europe (PO)